FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794633020> ?p ?o ?g. }

• W2794633020 endingPage "16546" @default.
• W2794633020 startingPage "16533" @default.
• W2794633020 abstract "// Miao Wang 1 and Alex Yuang-Chi Chang 1, 2 1 Department of Oncology, Johns Hopkins Singapore International Medical Center, Singapore 2 Department of Oncology, Johns Hopkins University, Baltimore, MD, USA Correspondence to: Alex Yuang-Chi Chang, email: achang10@jhmi.edu Keywords: molecular mechanism; growth inhibition; synergistic combination; gefitinib resistance; non-small cell lung cancer Received: December 19, 2017      Accepted: February 28, 2018      Published: March 27, 2018 ABSTRACT Epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) is the first choice of treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating EGFR mutations. However, single agent usually has limited efficacy due to heterogeneous resistant mechanisms of cancer cells. Thus drug combination therapy would offer more benefits by synergistic interactions and avoidance of resistance emergence. In this study, we selected 8 NSCLC cell lines with different genetic characteristics as research models to investigate the efficacy of 4 agents (gefitinib, cetuximab, afatinib and dasatinib) and their combinations. As a single agent, both afatinib and dasatinib showed more inhibition against cell proliferation than gefitinib and cetuximab. Afatinib combined with dasatinib demonstrated significantly high efficacy against 7 gefitinib-resistant NSCLC cell lines. Moreover, it reversed the resistance to the 4 studied single agents in PTEN mutated NSCLC cells. By studying the activity of EGFR, Src and their downstream signalling pathways including PI3K/PTEN/Akt, Ras/Raf/MEK/ERK, Src/FAK and JAK/Stat, we demonstrated the synergistic interaction between afatinib and dasatinib was not only due to their blockage of different signalling pathways but also the complemental inhibition of the related signalling molecules such as Stat3. We also found that the level of Src, Stat3, and MAPK may be useful biomarkers predicating synergism between afatinib and dasatinib for the treatment of gefitinib-resistant NSCLC cells." @default.
• W2794633020 created "2018-04-06" @default.
• W2794633020 creator A5008114425 @default.
• W2794633020 creator A5061082958 @default.
• W2794633020 date "2018-03-27" @default.
• W2794633020 modified "2023-09-28" @default.
• W2794633020 title "Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells" @default.
• W2794633020 cites W1553224996 @default.
• W2794633020 cites W1973186217 @default.
• W2794633020 cites W1978916359 @default.
• W2794633020 cites W1980982914 @default.
• W2794633020 cites W1998971866 @default.
• W2794633020 cites W1999213748 @default.
• W2794633020 cites W2003984225 @default.
• W2794633020 cites W2026279585 @default.
• W2794633020 cites W2032775411 @default.
• W2794633020 cites W2033520329 @default.
• W2794633020 cites W2040362887 @default.
• W2794633020 cites W2046524802 @default.
• W2794633020 cites W2050727804 @default.
• W2794633020 cites W2069336962 @default.
• W2794633020 cites W2073723168 @default.
• W2794633020 cites W2076178766 @default.
• W2794633020 cites W2081673273 @default.
• W2794633020 cites W2096008575 @default.
• W2794633020 cites W2098752359 @default.
• W2794633020 cites W2113564316 @default.
• W2794633020 cites W2121389354 @default.
• W2794633020 cites W2124254102 @default.
• W2794633020 cites W2133488997 @default.
• W2794633020 cites W2137004572 @default.
• W2794633020 cites W2137729785 @default.
• W2794633020 cites W2138536086 @default.
• W2794633020 cites W2141552280 @default.
• W2794633020 cites W2141584283 @default.
• W2794633020 cites W2142850084 @default.
• W2794633020 cites W2159480044 @default.
• W2794633020 cites W2161821474 @default.
• W2794633020 cites W2171179595 @default.
• W2794633020 cites W2320138981 @default.
• W2794633020 cites W2332183914 @default.
• W2794633020 cites W2744400235 @default.
• W2794633020 cites W2745482716 @default.
• W2794633020 cites W2748922433 @default.
• W2794633020 doi "https://doi.org/10.18632/oncotarget.24814" @default.
• W2794633020 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5893260" @default.
• W2794633020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29662665" @default.
• W2794633020 hasPublicationYear "2018" @default.
• W2794633020 type Work @default.
• W2794633020 sameAs 2794633020 @default.
• W2794633020 citedByCount "18" @default.
• W2794633020 countsByYear W27946330202018 @default.
• W2794633020 countsByYear W27946330202019 @default.
• W2794633020 countsByYear W27946330202020 @default.
• W2794633020 countsByYear W27946330202021 @default.
• W2794633020 countsByYear W27946330202022 @default.
• W2794633020 countsByYear W27946330202023 @default.
• W2794633020 crossrefType "journal-article" @default.
• W2794633020 hasAuthorship W2794633020A5008114425 @default.
• W2794633020 hasAuthorship W2794633020A5061082958 @default.
• W2794633020 hasBestOaLocation W27946330201 @default.
• W2794633020 hasConcept C121608353 @default.
• W2794633020 hasConcept C126322002 @default.
• W2794633020 hasConcept C143998085 @default.
• W2794633020 hasConcept C170493617 @default.
• W2794633020 hasConcept C184235292 @default.
• W2794633020 hasConcept C185592680 @default.
• W2794633020 hasConcept C2776256026 @default.
• W2794633020 hasConcept C2777609662 @default.
• W2794633020 hasConcept C2778087573 @default.
• W2794633020 hasConcept C2779438470 @default.
• W2794633020 hasConcept C2779536868 @default.
• W2794633020 hasConcept C2779998722 @default.
• W2794633020 hasConcept C2780580887 @default.
• W2794633020 hasConcept C2780586478 @default.
• W2794633020 hasConcept C42362537 @default.
• W2794633020 hasConcept C502942594 @default.
• W2794633020 hasConcept C526805850 @default.
• W2794633020 hasConcept C55493867 @default.
• W2794633020 hasConcept C57074206 @default.
• W2794633020 hasConcept C62478195 @default.
• W2794633020 hasConcept C71924100 @default.
• W2794633020 hasConcept C86554907 @default.
• W2794633020 hasConcept C98274493 @default.
• W2794633020 hasConceptScore W2794633020C121608353 @default.
• W2794633020 hasConceptScore W2794633020C126322002 @default.
• W2794633020 hasConceptScore W2794633020C143998085 @default.
• W2794633020 hasConceptScore W2794633020C170493617 @default.
• W2794633020 hasConceptScore W2794633020C184235292 @default.
• W2794633020 hasConceptScore W2794633020C185592680 @default.
• W2794633020 hasConceptScore W2794633020C2776256026 @default.
• W2794633020 hasConceptScore W2794633020C2777609662 @default.
• W2794633020 hasConceptScore W2794633020C2778087573 @default.
• W2794633020 hasConceptScore W2794633020C2779438470 @default.
• W2794633020 hasConceptScore W2794633020C2779536868 @default.
• W2794633020 hasConceptScore W2794633020C2779998722 @default.
• W2794633020 hasConceptScore W2794633020C2780580887 @default.
• W2794633020 hasConceptScore W2794633020C2780586478 @default.

• next